-
Brean Murray Carret & Co. Maintains Incyte Genomics at Buy, Lowers PT from $25 to $23
Wednesday, February 15, 2012 - 1:50pmRead More... -
Brean Murray Carret & Co. Maintains Masimooration at Buy, Raises PT from $24 to $26
Wednesday, February 15, 2012 - 7:42amRead More... -
Brean Murray Carret & Co. Lowers PT on Changyou Limited American Depositary Share from $32 to $29
Tuesday, February 7, 2012 - 8:07amRead More... -
Brean Murray Carret & Co. Downgrades Warnaco Group from Buy to Hold
Tuesday, February 7, 2012 - 7:46amRead More... -
Brean Murray Carret & Co. Downgrades Fossil from Buy to Hold
Tuesday, February 7, 2012 - 7:45amRead More... -
Brean Murray Carret & Co. Upgrades Urban Outfitters from Sell to Hold
Tuesday, February 7, 2012 - 7:44amRead More... -
Brean Murray Carret & Co. Lowers Wet Seal PT
Thursday, February 2, 2012 - 4:30pm | 116Read More...Brean Murray Carret & Co. tweaked its Wet Seal (NASDAQ: WTSLA) price target, reducing it from $5.50 to $5.00 in a research report published today. Brean Murray Carret & Co. has a Buy rating on the company. In the report, Brean Murray Carret & Co. states, "We are reducing our price...
-
Brean Murray Carret & Co. Raises Gilead Sciences PT To $60
Thursday, January 26, 2012 - 5:00pm | 126Read More...Brean Murray Carret & Co. raised its Gilead Sciences (NASDAQ: GILD) price target from $52 to $60 in a research report published today. Brean Murray Carret & Co. has a Buy rating on the company. In the report, Brean Murray Carret & Co. stated, "We believe Gilead is positioned to report...
-
Brean Murray Has Buy on Abercrombie & Fitch
Wednesday, October 12, 2011 - 8:14am | 111Read More...Brean Murray Carret & Co. is out with a research report on Abercrombie & Fitch (NYSE: ANF) and it has a Buy rating and a $85 price target on shares. In a note to clients, Brean Murray Carret & Co. writes, "Abercrombie & Fitch continues to use its domestic promotional atmosphere to...
-
Brean Murray Has Buy on Tivo
Friday, October 7, 2011 - 8:26am | 44Read More...Brean Murray Carret & Co. is out with a research report on Tivo (NASDAQ: TIVO) and it has a Buy rating and a $14 price target. Shares of TIVO gained 24 cents yesterday to close at $9.66, a gain of 2.55%.
-
Brean Murray Has Buy on South Jersey Industries
Friday, October 7, 2011 - 8:24am | 44Read More...Brean Murray Carret & Co. is out with a research report on South Jersey Industries (NYSE: SJI) and it has a Buy rating and a $58 price target on shares. Shares of SJI closed at $51.31, a gain of $1.24.
-
UPDATE: Brean Murray Raising Price Target On PVH Corp
Wednesday, August 31, 2011 - 7:49am | 50Read More...Brean Murray Carret & Co. is out with a research report on PVH Corp (NYSE: PVH) and is raising its price target to $85 from $80. It has a Buy rating on shares. Shares of PVH gained 41 cents yesterday to close at $64.90, a gain of 0.64%.
-
Brean Murray Initiating Coverage On Onyx Pharmaceuticals, Inc. (NASDAQ)
Wednesday, August 31, 2011 - 7:47am | 41Read More...Brean Murray Carret & Co. is out with a research report on Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) and it is initiating coverage with a Hold rating. Shares of ONXX closed at $33.69 yesterday, down 1 cent.
-
Brean Murray Carret & Co. Lowers PT On BYI To $43
Tuesday, August 23, 2011 - 8:42am | 73Read More...Brean Murray Carret & Co. has lowered its price target from $51 to $43 on Bally Technologies (NYSE: BYI) but is maintaining the stocks Buy rating in light of the company's latest guidances. Says Brean Murray Carret & Co., in its report, “We believe management's guidance for FY12 of ‘at...
-
Brean Murray Carret & Co. Initiates Coverage On HGSI
Tuesday, August 23, 2011 - 8:17am | 109Read More...Brean Murray Carret & Co. are initiating coverage on Human Genome Sciences (NASDAQ: HGSI) with a Buy rating and a price target set at $22. Says Brean Murray Carret &Co., in the report, “ The company's key driver is Benlysta, a novel IV therapeutic now approved as a chronic therapy to treat...
